191 related articles for article (PubMed ID: 36985681)
1. Decoding the Conformational Selective Mechanism of FGFR Isoforms: A Comparative Molecular Dynamics Simulation.
Zhang M; Yasen M; Lu S; Ma DN; Chai Z
Molecules; 2023 Mar; 28(6):. PubMed ID: 36985681
[TBL] [Abstract][Full Text] [Related]
2. Theoretical studies on FGFR isoform selectivity of FGFR1/FGFR4 inhibitors by molecular dynamics simulations and free energy calculations.
Fu W; Chen L; Wang Z; Kang Y; Wu C; Xia Q; Liu Z; Zhou J; Liang G; Cai Y
Phys Chem Chem Phys; 2017 Feb; 19(5):3649-3659. PubMed ID: 28094372
[TBL] [Abstract][Full Text] [Related]
3. Deciphering the molecular mechanisms of selective non-covalency demonstrated differentially by 9-Allylnaphtho[1,8-ef]isoindole-7,8,10(9H)-trione (C11) against fibroblast growth factor receptors 1-4.
Olotu FA; Soliman MES
J Biomol Struct Dyn; 2023 Apr; 41(6):2419-2430. PubMed ID: 35105282
[TBL] [Abstract][Full Text] [Related]
4. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J
Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459
[TBL] [Abstract][Full Text] [Related]
5. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
Sootome H; Fujita H; Ito K; Ochiiwa H; Fujioka Y; Ito K; Miura A; Sagara T; Ito S; Ohsawa H; Otsuki S; Funabashi K; Yashiro M; Matsuo K; Yonekura K; Hirai H
Cancer Res; 2020 Nov; 80(22):4986-4997. PubMed ID: 32973082
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models.
Chew NJ; Lim Kam Sian TCC; Nguyen EV; Shin SY; Yang J; Hui MN; Deng N; McLean CA; Welm AL; Lim E; Gregory P; Nottle T; Lang T; Vereker M; Richardson G; Kerr G; Micati D; Jardé T; Abud HE; Lee RS; Swarbrick A; Daly RJ
Breast Cancer Res; 2021 Aug; 23(1):82. PubMed ID: 34344433
[TBL] [Abstract][Full Text] [Related]
7. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
Xie L; Su X; Zhang L; Yin X; Tang L; Zhang X; Xu Y; Gao Z; Liu K; Zhou M; Gao B; Shen D; Zhang L; Ji J; Gavine PR; Zhang J; Kilgour E; Zhang X; Ji Q
Clin Cancer Res; 2013 May; 19(9):2572-83. PubMed ID: 23493349
[TBL] [Abstract][Full Text] [Related]
8. FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).
Katoh M
Int J Mol Med; 2016 Jul; 38(1):3-15. PubMed ID: 27245147
[TBL] [Abstract][Full Text] [Related]
9. From Fragment to Lead: De Novo Design and Development toward a Selective FGFR2 Inhibitor.
Turner LD; Trinh CH; Hubball RA; Orritt KM; Lin CC; Burns JE; Knowles MA; Fishwick CWG
J Med Chem; 2022 Jan; 65(2):1481-1504. PubMed ID: 34780700
[TBL] [Abstract][Full Text] [Related]
10. The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.
Nakanishi Y; Akiyama N; Tsukaguchi T; Fujii T; Sakata K; Sase H; Isobe T; Morikami K; Shindoh H; Mio T; Ebiike H; Taka N; Aoki Y; Ishii N
Mol Cancer Ther; 2014 Nov; 13(11):2547-58. PubMed ID: 25169980
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast growth factor (FGF), FGF receptor (FGFR), and cyclin D1 (CCND1) DNA methylation in head and neck squamous cell carcinomas is associated with transcriptional activity, gene amplification, human papillomavirus (HPV) status, and sensitivity to tyrosine kinase inhibitors.
Bao Y; Gabrielpillai J; Dietrich J; Zarbl R; Strieth S; Schröck F; Dietrich D
Clin Epigenetics; 2021 Dec; 13(1):228. PubMed ID: 34933671
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a Selective and Orally Bioavailable FGFR2 Degrader for Treating Gastric Cancer.
Ma L; Li Y; Luo R; Wang Y; Cao J; Fu W; Qian B; Zheng L; Tang L; Lv X; Zheng L; Liang G; Chen L
J Med Chem; 2023 Jun; 66(11):7438-7453. PubMed ID: 37220310
[TBL] [Abstract][Full Text] [Related]
13. Molecular dynamics simulations reveal phosphorylation-induced conformational dynamics of the fibroblast growth factor receptor 1 kinase.
Mahapatra S; Jonniya NA; Koirala S; Kar P
J Biomol Struct Dyn; 2024 Apr; 42(6):2929-2941. PubMed ID: 37160693
[TBL] [Abstract][Full Text] [Related]
14. Decoupling the dynamic mechanism revealed by FGFR2 mutation-induced population shift.
Zhang Y; Yin XL; Ji M; Chen Y; Chai Z
J Biomol Struct Dyn; 2024; 42(4):1940-1951. PubMed ID: 37254996
[TBL] [Abstract][Full Text] [Related]
15. Differential roles of fibroblast growth factor receptors (FGFR) 1, 2 and 3 in the regulation of S115 breast cancer cell growth.
Tarkkonen KM; Nilsson EM; Kähkönen TE; Dey JH; Heikkilä JE; Tuomela JM; Liu Q; Hynes NE; Härkönen PL
PLoS One; 2012; 7(11):e49970. PubMed ID: 23185502
[TBL] [Abstract][Full Text] [Related]
16. Dlg-1 Interacts With and Regulates the Activities of Fibroblast Growth Factor Receptors and EphA2 in the Mouse Lens.
Lee S; Shatadal S; Griep AE
Invest Ophthalmol Vis Sci; 2016 Feb; 57(2):707-18. PubMed ID: 26906157
[TBL] [Abstract][Full Text] [Related]
17. Thalidomide and Its Analogs Differentially Target Fibroblast Growth Factor Receptors: Thalidomide Suppresses FGFR Gene Expression while Pomalidomide Dampens FGFR2 Activity.
Sundaresan L; Kumar P; Manivannan J; Balaguru UM; Kasiviswanathan D; Veeriah V; Anishetty S; Chatterjee S
Chem Res Toxicol; 2019 Apr; 32(4):589-602. PubMed ID: 30834740
[TBL] [Abstract][Full Text] [Related]
18. Role of fibroblast growth factor receptors (FGFR) and FGFR like-1 (FGFRL1) in mesenchymal stromal cell differentiation to osteoblasts and adipocytes.
Kähkönen TE; Ivaska KK; Jiang M; Büki KG; Väänänen HK; Härkönen PL
Mol Cell Endocrinol; 2018 Feb; 461():194-204. PubMed ID: 28923346
[TBL] [Abstract][Full Text] [Related]
19. Nuclear Fibroblast Growth Factor Receptor Signaling in Skeletal Development and Disease.
Tuzon CT; Rigueur D; Merrill AE
Curr Osteoporos Rep; 2019 Jun; 17(3):138-146. PubMed ID: 30982184
[TBL] [Abstract][Full Text] [Related]
20. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.
Gozgit JM; Wong MJ; Moran L; Wardwell S; Mohemmad QK; Narasimhan NI; Shakespeare WC; Wang F; Clackson T; Rivera VM
Mol Cancer Ther; 2012 Mar; 11(3):690-9. PubMed ID: 22238366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
